Previous 10 | Next 10 |
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" PR Newswire LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutica...
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology PR Newswire LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company develo...
Nanocap pharma Pulmatrix, Inc. ( NASDAQ: PULM ) dropped ~18% in the morning hours Wednesday after announcing topline results from a Phase 1 trial for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine (DHE) targeting acute migraine. The Australia-based study in...
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine PR Newswire PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minut...
Pulmatrix press release ( NASDAQ: PULM ): Q3 GAAP EPS of -$1.45 beats by $0.06 . Revenue of $1.87M (+74.8% Y/Y) beats by $0.71M . For further details see: Pulmatrix GAAP EPS of -$1.45 beats by $0.06, revenue of $1.87M beats by $0.71M
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash...
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine PR Newswire Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects ph...
Pulmatrix press release ( NASDAQ: PULM ): Q2 GAAP EPS of -$1.36 beats by $0.15 . Revenue of $1.33M (-39.5% Y/Y) beats by $0.17M . Total cash and cash equivalents balance as of June 30, 2022 was $42.9 million. For further details see: Pulmatrix GAAP EP...
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 mil...
Pulmatrix ( NASDAQ: PULM ) on Tuesday said it had dosed the first five subjects in its phase 1 trial evaluating its acute migraine treatment PUR3100. The early-stage trial has been designed to assess the safety, tolerability and pharmacokinetics of inhaled PUR3100. The...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...